Drug Trial Radar · NCT01721733
Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Oct 31, 2012
Primary completion
Feb 28, 2015
Study completion May 31, 2015
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Axio Research. LLC
- First posted
- Nov 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and disease associated biomarkers.
Conditions
- Leigh Syndrome
Interventions
PlaceboDrug
EPI-743 15 mg/kgDrug
EPI-743 5 mg/kgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3Time frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
Akron Children's Hospital
Akron, Ohio
Baylor College of Medicine
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.